Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Aiko N. Vigo"'
Publikováno v:
International Journal of Mycobacteriology, Vol 13, Iss 3, Pp 237-246 (2024)
To systematize published laboratory methods to inactivate Mycobacterium tuberculosis (MTB) and to describe their effectiveness. We carried out a review of the scientific literature to identify the publications that reported methods for the inactivati
Externí odkaz:
https://doaj.org/article/6717e75b9d69415e9c6f7fec5000ede6
Autor:
Zully M. Puyén, David Santos-Lázaro, Aiko N. Vigo, Jorge Coronel, Miriam J. Alarcón, Vidia V. Cotrina, David A. J. Moore
Publikováno v:
BMC Infectious Diseases, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Tuberculosis (TB) is a communicable, preventable and curable disease caused by the bacterium Mycobacterium tuberculosis (MTB). Peru is amongst the 30 countries with the highest burden of multidrug-resistant tuberculosis (MDR-TB) w
Externí odkaz:
https://doaj.org/article/10f0dd1b957b4ab6aca9bbea4249e40e
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Abstract Peru has the highest burden of multidrug-resistant tuberculosis in the Americas region. Since 1999, the annual number of extensively drug-resistant tuberculosis (XDR-TB) Peruvian cases has been increasing, becoming a public health challenge.
Externí odkaz:
https://doaj.org/article/4958d1d00e5e4215960b31bad5879328
Autor:
Zully M. Puyen, David Santos-Lázaro, Aiko N. Vigo, Jorge Coronel, Miriam J. Alarcón, Vidia V. Cotrina, David A.J. Moore
Peru is amongst the 30 countries with the highest burden of multidrug-resistant tuberculosis worldwide. In the fight against drug-resistant tuberculosis, the UKMYC6 microtiter plate was developed and validated by the CRyPTIC project. Our objective wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::33eab6d4065f0f2d8c8362597bb9e57d
https://doi.org/10.1101/2022.03.29.486329
https://doi.org/10.1101/2022.03.29.486329
Publikováno v:
Revista Peruana de Medicina Experimental y Salud Pública. 36:636-45
Objetivos. Sistematizar la información disponible referente a las mutaciones que confieren resistencia a los fármacos antituberculosis de primera línea. Materiales y métodos. Se realizó una revisión sistemática de la literatura científica par
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de65c20349f193c960c5c9aafba0553f
https://doi.org/10.17843/rpmesp.2019.364.4722
https://doi.org/10.17843/rpmesp.2019.364.4722
Publikováno v:
Universidad Peruana de Ciencias Aplicadas (UPC)
Repositorio Academico-UPC
UPC-Institucional
Universidad Peruana de Ciencias Aplicadas
instacron:UPC
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Repositorio Academico-UPC
UPC-Institucional
Universidad Peruana de Ciencias Aplicadas
instacron:UPC
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Peru has the highest burden of multidrug-resistant tuberculosis in the Americas region. Since 1999, the annual number of extensively drug-resistant tuberculosis (XDR-TB) Peruvian cases has been increasing, becoming a public health challenge. The obje
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6c451d1c68c6870abdb6be26efeec8c